TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06471712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-LNC1007 Injection
Description: Healthy volunteers will receive 1 MBq/kg and cancer patients will receive 3.7 MBq/kg. The injection will be carried out on the scan bed via an IV indwelling catheter. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.
Study: NCT05543239

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation(TaVNS)
Description: Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS) works by stimulating the auricular branches of the vagus nerve (mainly distributed in the concha cavity and conchae) through electrical impulses.Electrodes were placed on the concha of the left ear after cleaning the skin of the concha with a small disposable alcohol pad. Stimulation pulses (frequency 30 Hz, pulse width 300 us) were generated by TaVNS device, the amplitude was increased within 30 seconds to the subject produced a tingling sensation, and then descend within 15 seconds to the maximum tolerable amount without pain. Inform the subject that target stimulus has been reached, then stimulate for 30 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Auricular Vagus Nerve Stimulation(SS)
Description: Place electrodes on the concha of the left ear after cleaning the skin of the concha with a small disposable alcohol pad. The same stimulation pulses (30 Hz frequency, 300 us pulse width) were generated by the same device, the amplitude was increased within 30 seconds to the subject produced a tingling sensation, and then ramps down to zero stimulus over 15 seconds. The subjects were told that the target stimulus has been reached. Patients receive sham stimulation for 30minutes.
Study: NCT05875649

Intervention type: COMBINATION_PRODUCT
Intervention: CLAG
Description: Acute myeloid leukemia patients are re-induced by CLAG Regimen after first-induction failure
Study: NCT06277505

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Take prebiotics and probiotics
Description: Take 3.5g prebiotic +2g prebiotic twice a day before meals; At the same time, lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle guidance
Description: lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle guidance
Description: lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
Study: NCT05677386

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Primary preventive treatment guided by CTCA
Description: Computed tomography coronary angiography (CTCA)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cardiovascular risk Score
Description: Systematic COronary Risk Evaluation 2 model for cardiovascular risk prediction
Study: NCT06609031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic mucosal resection
Description: The SSLs less than 10mm in size in this group will be treated by EMR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold snare polypectomy
Description: The SSLs less than 10mm in size in this group will be treated by CSP
Study: NCT04706936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA CAR-T
Description: Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: 300mg/m2/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d
Study: NCT06156553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PULSE school-based intervention
Description: PULSE - School-based intervention is a feasibility study designed to support active travel among adolescents. The curricular intervention is designed to increase the students' health literacy as well as their autonomous motivation for active travel. The intervention will last for 6 weeks during fall 2023. The first session will be delivered by a science and education center, and the consecutive sessions will be delivered by teachers. PULSE sessions will contribute to the attainment of specific competence aims related to two interdisciplinary topics, Health and life skills and Sustainability, as defined in PE, social science, and science. The research question is the following: Can increased attention to the barriers and benefits of active travel increase physical activity for youths?
Study: NCT05640492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training for Depression in Later Life (MCT-Silver)
Description: MCT-Silver consists of eight modules, each of which begins with psychoeducational and normalizing elements. A mastery is presented through examples and exercises, and the fallibility of human cognition is discussed and illustrated. In a second phase, the pathological extremes of each cognitive bias are highlighted and the participant is shown how the exacerbation of (normal) thinking biases can lead to problems in daily life. It is intended with this exercise that participants learn how to identify and mitigate cognitive traps. Dysfunctional coping strategies (social isolation and negative thoughts) are highlighted, and suggestions for replacing them with adaptive strategies are given. Homework assignments are distributed at the end of each session (Schneider et al., 2018).
Study: NCT04351698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast is used to treat and prevent asthma. It will decrease the symptoms and the number of acute asthma attacks. However this medicine should not be used to relieve an asthma attack that has already started.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Inert chewable tablet with no therapeutic value
Study: NCT06297720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hydration
Description: * Researchers moisten the patient's throat with a wet cotton swab. If no nausea or vomiting occurs after five minutes, proceed to the next stage.~* Provide an ice cube of potable water for the patient to hold in their mouth. If no nausea or vomiting occurs after ten minutes, proceed to the next stage.~* Offer 10-20ml of potable water for the patient to drink under medical supervision. If no nausea or vomiting occurs and the patient requests more water, administer 10-20ml every ten minutes, assessing for any adverse effects each time. The total water intake should not exceed 500ml.
Study: NCT05860829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational
Description: Caregivers of children with ASD will be sampled that are enrolled in Autism specialized Schools or centers. Tools and group education sessions will be developed in Urdu, English and Sindhi language. A caregiver education program session will be conducted by a practicing dentist and a registered dietitian in Urdu1 and English. Considering the ease of caregivers, cost-effectiveness and managing flexible hours, tele-health will be practiced for education program. A post-test will be conducted to assess the impact of the educational program on the knowledge of caregivers.
Study: NCT06198751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6.0 mg/kg of TQB2102 for injection
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 6.0 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg of TQB2102 for injection
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 7.5 mg/kg.
Study: NCT04845399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Description: Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.
Study: NCT06498284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM-002-1005
Description: HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM-002-1005
Description: HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM-002-1005
Description: HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM-002-1005
Description: HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets
Study: NCT06378723

Intervention type: OTHER
Intervention: Balance Tests
Description: With the scales and tests the children trunk control, quality of upper extremity skills, single leg stance duration will be measured

Intervention type: OTHER
Intervention: Balance Tests
Description: With the scales and tests the children trunk control, quality of upper extremity skills, single leg stance duration will be measured
Study: NCT06359197

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Finger prick and collection on Whatman Protein 903 Saver Cards
Description: The Whatman Protein 903 Saver Card is a specialized filter paper designed for the collection, storage, and elution of biological samples, including blood. It contains five half-inch circles that hold 75 to 80 µL of blood, making it an efficient and reliable method of obtaining dried blood spot (DBS) samples. The participant's finger will be pricked using a sterile, disposable lancet, and drops of blood will be collected on the Whatman 903 Protein Saver Card to fill nine ½ inch discs via capillary action. The blood spots will be allowed to dry at ambient temperature (21°C) for two hours. Whatman Protein 903 Saver Cards undergo strict quality control and GMP manufacturing standards, which ensures high quality and reproducibility.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous Sampling
Description: Blood will be collected from the medial cubital vein according to the standard venous blood sampling protocol into an EDTA tube with a volume up to 4mL.
Study: NCT06198270

Intervention type: OTHER
Group type: OTHER
Intervention: Closed Kinetic Chain Exercise
Description: Closed chain exercise plan of 5 exercises, 10reps x 3sets of each, 3 days in a week for 4-weeks, all values measured before and after 4-weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training with K Tape
Description: Neuromuscular training plan of 5 exercises, 10reps x 3sets of each, 3 days in a week, for 4-weeks, all values measured before and after 4-weeks. Just After the session k-tape applied.
Study: NCT05627869

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus thoracic plane block
Description: TTPB group will receive bilateral ultrasound-guided transversus thoracic muscle plane block using 20 ml of bupivacaine 0.25% for each side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pecto intercostal fascial block
Description: PIFB group will receive bilateral ultrasound-guided Pecto-intercostal fascial plane block using 20 ml of bupivacaine 0.25% for each side.
Study: NCT04584671

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized Xenon-129 MRI of the lungs
Description: Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized Xenon-129 MRI of the lungs
Description: Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography (CT)
Description: Participants will undergo a CT scan of the thoracic cavity

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography (CT)
Description: Participants will undergo a CT scan of the thoracic cavity

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests (PFT)
Description: Participants will have their lung function evaluated using PFT

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests (PFT)
Description: Participants will have their lung function evaluated using PFT

Intervention type: DIAGNOSTIC_TEST
Intervention: Six Minute Walk Test (6MWT)
Description: Participants will perform the six minute walk test as a measure of exercise capacity

Intervention type: DIAGNOSTIC_TEST
Intervention: Six Minute Walk Test (6MWT)
Description: Participants will perform the six minute walk test as a measure of exercise capacity

Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum analysis
Description: Participants will provide a sputum sample that will be analysed for eosinophils

Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum analysis
Description: Participants will provide a sputum sample that will be analysed for eosinophils

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analysis
Description: Participants will have their blood drawn and analysed for eosinophil count.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analysis
Description: Participants will have their blood drawn and analysed for eosinophil count.

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
Study: NCT04603742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg of Anakinra will be mixed with 100 mL of 0.9% saline solution for IV administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: The placebo preparation will consist of a 100 mL of 0.9% saline solution without the addition of anakinra.
Study: NCT05671354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the auto-wrapping commode chair
Description: The auto-wrapping commode chairs will seal off the excretions in a plastic bag when a button is pressed, and then prepare a new bag for next excretions. The sealed excretions will then be disposed of as usual garbage. The same staff, who are responsible for disposing of the excretions from the commodes in the pre-test, will dispose of the excretions from the auto-wrapping commode chairs during the trial.
Study: NCT06450236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel 10 MG
Description: 1 tablet of Perampanel Tablets 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fycompa 10Mg Tablet
Description: 1 tablet of Perampanel Tablets 10mg
Study: NCT05577325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control group will be followed without health education
Description: After the whole universe is evaluated in terms of percentile value, students with a percentile value of ≥95 will be filled with a pre-application form in terms of inclusion criteria in the research. Randomization will be made by drawing lots from the closed envelope in a way that will be homogeneously distributed between the classes and genders of the students who accept to participate in the research. Pre-tests will be given to those who accept to participate in the research. In the first week of the training, pedometers will be distributed and their use will be explained. This group is follow up without planned education. At the end of the sixth month of the study, the post-test data collection forms, excluding the personal information form, will be applied to the intervention group and anthropometric measurements will be made again.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control group will be followed without health education
Description: After the whole universe is evaluated in terms of percentile value, students with a percentile value of ≥95 will be filled with a pre-application form in terms of inclusion criteria in the research. Randomization will be made by drawing lots from the closed envelope in a way that will be homogeneously distributed between the classes and genders of the students who accept to participate in the research. Pre-tests will be given to those who accept to participate in the research. In the first week of the training, pedometers will be distributed and their use will be explained. This group is follow up without planned education. At the end of the sixth month of the study, the post-test data collection forms, excluding the personal information form, will be applied to the intervention group and anthropometric measurements will be made again.
Study: NCT04676789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Pegaspargase 2500IU/m2 administered by intramuscular injection on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Definitive intensity-modulated radiotherapy (IMRT)
Description: Definitive intensity-modulated radiotherapy (IMRT) of 50 Gy will be given in 25 days
Study: NCT06359197

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Sampling
Description: Blood will be collected from the medial cubital vein according to the standard venous blood sampling protocol into an EDTA tube with a volume up to 4mL.
Study: NCT05599347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Pill
Description: Tablet - 500 mg azithromycin (as dihydrate)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm
Study: NCT05140252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast cancer decision aid
Description: The decision aid is tailored from a previously published aid, specific to women ≥70 with early-stage breast cancer. The aid will be delivered via mail or electronically per patient preference before the patient's initial appointment with a surgeon.
Study: NCT05513755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardioneuroablation
Description: Endocardical radiofrequency ablation of vagal ganglia located close to pulmonary veins antra and interatrial septum.
Study: NCT05182307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DurAVR™ THV System
Description: Transcatheter Aortic Valve Implantation (TAVI) Procedure
Study: NCT06486337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMOP±R
Description: Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 4 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1, every 4 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 2-3 mg/m2 on day 1), every 4 weeks; Drug: Prednisone Prednisone (100 mg) will be taken orally from day 1-5(Or equivalent dose of dexamethasone at 15mg), every 4 weeks; Drug: Rituximab Rituximab (375mg/m\^2) on day 0, every 4 weeks, only with CD20-positive lymphomas are evaluated by the investigator.
Study: NCT04849299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 550 mg + cyclosporine
Description: 550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered simultaneously on Day 7 Other Names: AT-527 is also known as R07496998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 550 mg + cyclosporine
Description: 550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered on Day 7 (with dosing offset by 2 hrs) Other Names: AT-527 is also known as R07496998
Study: NCT05515354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of nicotine replacement therapy start date
Description: Nicotine replacement therapy and abstinence from smoking are initiated at a specific period with regard to the menstrual cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of nicotine replacement therapy start date
Description: Nicotine replacement therapy and abstinence from smoking are initiated at a specific period with regard to the menstrual cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy Agent
Description: Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks. Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches. For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy Agent
Description: Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks. Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches. For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy Agent
Description: Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks. Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches. For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.
Study: NCT05580835

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET MRI with PSMA
Description: A whole-body PET using PSMA as a radiotracer associated to an upper abdomen MRI with gadoxetic acid as contrast agent
Study: NCT05643755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative image-based education
Description: Intervention group: education handout containing pictographic and written education material on wound appearance following primary closure after Mohs Micrographic Surgery (MMS) or Wide Local Excision (WLE)
Study: NCT06319157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: minimal access breast reconstruction with a latissimus dorsi muscle flap
Description: minimal access breast reconstruction with a latissimus dorsi muscle flap

Intervention type: DEVICE
Group type: OTHER
Intervention: conventional breast reconstruction with a latissimus dorsi muscle flap
Description: conventional breast reconstruction with a latissimus dorsi muscle flap
Study: NCT04773067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: Around 3300 adult subjects and 330 adolescent subjects will receive 2 doses of 100 µg UB-612 vaccine. The subjects will be invited to have the 3rd dose after unblinded.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Around 550 adult subjects and 55 adolescent subjects will receive 2 doses of normal saline 0.9%.